CEO of Novamab delivered a wonderful speech at the ACCESS CHINA Boston Forum

A leading global enterprise in the research and development of innovative sdAb drugs

The offline event of Yaotong China Boston Forum, jointly organized by Yafa Capital, CHBD, China Europe Alumni Healthcare Industry Association, Wisdom Pharmaceuticals, and Global Law Firm, successfully concluded on June 4th. At this grand event in the pharmaceutical industry, hundreds of representatives from pharmaceutical industry executives, BD professionals, investment institutions, and others from around the world gathered to discuss and share the latest trends and achievements of Asian countries such as China, Japan, and South Korea around the theme of Asia Biomedical Innovation and International Cooperation. The keynote speeches, roundtable discussions, high-quality project roadshows, and the Ruizhi Pharmaceuticals China Reception Dinner have made this forum an important platform for communication and cooperation in the pharmaceutical field.

Dr. Yakun Wan, CEO of Novamab, was invited to conduct a company roadshow. In the speech, Dr. Wan shared the important breakthroughs and innovative achievements of Novamab in the field of single domain antibody (sdAb), as well as the company's strategic planning and vision in sdAb development and industrialization. Dr. Wan explained in simple terms the role of sdAb drugs in changing patients' lives, enhancing the convenience and effectiveness of treatment. He emphasized the leading position of Novamab in the full process development of sdAbs and looked forward to the enormous potential of this technology in pharmaceutical innovation.

Dr. Wan's speech sparked widespread interest and active discussion among the attendees. They showed strong interest in the innovative technology of Novamab and the application prospects of sdAb drugs, and interest in cooperation.

About ACCESS CHINA

‍

ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations.

About YAFO Capital

Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., and London offices. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions in the past four years. 

About Novamab

Shanghai Novamab Biopharmaceuticals Co., Ltd. is an innovative biopharmaceutical enterprise committed to sdAb drug development and industrialization. Founded in October 2017, the company is located in Shanghai International Medical Park. It has Novamab has established the first and only sdAb development platform covering the full biopharmaceutical process in China. As of April 2023, we have nearly 90 employees, applied for nearly 70 patents with 25 authorized.

Novamab has independently created five core technology platforms: sdAb rapid screening platform, Pichia pastoris based CMC platform, biologcial drug inhalation platform, long-acting sdAb platform and bispecific sdAb platform. Each platform has unique leading technology, which makes it more competitive.The powerful paltform make it possible to rapidly bring the candidates to commercialization. The completion of the 500L GMP workshop for sdAb production using Pichia pastoris fills the industry gap in this field, which is extremely scarce and competitive.

Novamab has developed dozens of sdAb drugs, covering respiratory, anti-infection, ophthalmology and oncology. Currently, it has obtained three clinical approvals. LQ036 and LQ043 developed by Novamab have overturned the existing treatment methods for respiratory diseases, both of which are the world's first inhalable sdAb drug for their respective target. Phase I trials of LQ036 have been conducted in China and Australia, both demonstrating excellent safety and tolerability. The LQ036 IND files for COPD treatment will be submitted soon. In addition, phase I trial of LQ043 in China has completed the dosing of the third group of subjects. Most moderate to severe asthmatics would benefit from the LQ036 and LQ043 considering their mechanism of action.